Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NI006 in ATTR Cardiomyopathy
NCT04360434Phase 1Completed
- Sponsor
- Neurimmune
- Start
- Feb 2020
- Primary completion
- Jul 2023
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial in amyloid transthyretin cardiomyopathy (ATTR-CM) comparing NI006 with Placebo (2 arms). Primary endpoint: Number and proportion of treatment emergent adverse events and serious adverse events and clinically significant changes in laboratory parameters, vital signs, electrocardiogram and echocardiogram up to 22 months. Started Feb 2020; status: completed.
02
Drugs
cliramitug
03
Conditions
amyloid transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT04360434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04360434.